FOXO3 and hepatocellular carcinoma: Therefore, we decided to treat our chemoresistant HCC cells with this second-line drug to test whether the efficacy of regorafenib under a cellular context of sorafenib resistance is partially due to the inhibition of the FOXO3-mediated autophagy.